Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Takeda Sheds More Non-Core Assets, Employees In $670m Orifarm Deal

Executive Summary

Danish firm picks up portfolio and manufacturing sites, along with around 600 employees.

You may also be interested in...



Cheplapharm Benefits As Takeda Sheds More Older Products

Japanese major presses on with post-Shire divestments even after passing strategic target.

Novartis Xiidra Buy Looks Even Pricier With File Pulled In EU

A year after inking a multi-billion dollar deal to get hold of the Takeda eye drop, Novartis has given up on getting approval for Xiidra in Europe with the EMA unconvinced about the therapy's efficacy.

Takeda Forecasts Tripling In Reported Op Profit Despite Virus Uncertainties

While it has seen no coronavirus-related business impact so far and uncertainties remain, Takeda expects lower costs related to the Shire acquisition to propel its profits this fiscal year.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

LL1127674

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel